• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by IN8bio Inc.

    3/13/25 5:02:35 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INAB alert in real time by email
    S-8 1 d936078ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 13, 2025

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IN8BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   82-5462585

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    350 5th Avenue, Suite 5330

    New York, New York

      10118
    (Address of Principal Executive Offices)   (Zip Code)

    Amended and Restated 2023 Equity Incentive Plan

    (Full titles of the plans)

    William Ho

    President and Chief Executive Officer

    IN8bio, Inc.

    350 5th Avenue, Suite 5330, New York, New York 10118

    (Name and address of agent for service)

    (646) 600-6438

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Jaime L. Chase

    Cooley LLP

    1299 Pennsylvania Avenue, NW, Suite 700

    Washington, DC 20004

    (202) 842-7800

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Pursuant to General Instruction E of Form S-8, IN8bio, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 3,624,163 shares of common stock under the Registrant’s 2023 Amended and Restated Equity Incentive Plan (the “Plan”), pursuant to the provisions of the Plan, which provide for an annual automatic increase in the number of shares of common stock reserved for issuance under the Plan.

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Commission:

     

    (a)

    the contents of the Registrant’s Registration Statements on Form S-8, previously filed with the Commission on September  10, 2021, as amended on August 18, 2023 (File No.  333-259458), May  12, 2022 (333-264893), as amended on August  18, 2023, August 18, 2023 (File No.  333-274092) and January 19, 2024 (333-276614);

     

    (b)

    the Registrant’s Annual Report on Form 10-K (File No. 001-39692) for the fiscal year ended December 31, 2024, filed with the Commission on March 13, 2025;

     

    (c)

    the Registrant’s Current Reports on Form 8-K (File No. 001-39692), filed on February  7, 2025, February  11, 2025 and March 5, 2025 to the extent the information in and exhibits to such reports are filed and not furnished; and

     

    (d)

    the description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39692), filed with the Commission on November 10, 2020, under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

    Item 4. Description of Securities.

    Not applicable.


    Item 5. Interests of Named Experts and Counsel.

    As of the date hereof, partners of Cooley LLP and GC&H Investments, LLC, an entity that is comprised of partners and associates of Cooley LLP, beneficially own an aggregate of 173,937 shares of the Registrant’s common stock.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s amended and restated certificate of incorporation provides for indemnification of the Registrant’s directors to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s amended and restated bylaws provide for indemnification of the Registrant’s directors, officers, employees and other agents to the maximum extent permitted by law.

    The Registrant has entered into indemnification agreements with the Registrant’s directors and officers, whereby the Registrant has agreed to indemnify the Registrant’s directors and officers to the fullest extent permitted by law, including advancement of expenses incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

    The Registrant maintains insurance policies that indemnify the Registrant’s directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     

    Exhibit
    Number
      

    Exhibit Description

     4.1    Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-39692), filed with the Commission on August 3, 2021).
     4.2    Second Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39692), filed with the Commission on December 7, 2023).
     5.1*    Opinion of Cooley LLP.
    23.1*    Consent of Independent Registered Public Accounting Firm.
    23.2*    Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on the signature page to this Registration Statement).
    99.1    Amended and Restated 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39692), filed with the Commission on August 10, 2023).
    99.2    Forms of Option Grant Notice and Option Agreement under the Amended and Restated 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39692), filed with the Commission on August 10, 2023).
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    Item 9. Undertakings.

    A. The undersigned Registrant hereby undertakes:

    1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on March 13, 2025.

     

    IN8bio, Inc.
    By:  

    /s/ William Ho

      William Ho
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William Ho and Patrick McCall, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


    Signature    Title    Date

    /s/ William Ho

    William Ho

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

       March 13, 2025

    /s/ Patrick McCall

    Patrick McCall

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       March 13, 2025

    /s/ Alan S. Roemer

    Alan S. Roemer

       Chairman of the Board of Directors    March 13, 2025

    /s/ Peter Brandt

    Peter Brandt

       Director    March 13, 2025

    /s/ Corinne Epperly

    Corinne Epperly

       Director    March 13, 2025

    /s/ Emily T. Fairbairn

    Emily T. Fairbairn

       Director    March 13, 2025

    /s/ Jeremy R. Graff

    Jeremy R. Graff

       Director    March 13, 2025

    /s/ Luba Greenwood

    Luba Greenwood

       Director    March 13, 2025

    /s/ Travis Whitfill

    Travis Whitfill

       Director    March 13, 2025
    Get the next $INAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INAB

    DatePrice TargetRatingAnalyst
    3/18/2024$7.50Buy
    Laidlaw
    8/30/2022$14.00Buy
    H.C. Wainwright
    1/24/2022$19.00 → $9.00Buy
    B. Riley Securities
    8/24/2021$12.00Buy
    Mizuho
    8/23/2021$19.00Buy
    B. Riley Securities
    More analyst ratings

    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:26 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President and COO Rochlin Kate

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:23 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by EVP and CSO Lamb Lawrence

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:27 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IN8bio to Present at Upcoming Investor and Scientific Conferences in February

    NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360° ConferenceDate: Thursday, February 12, 2026Time: 1:20 p.m. – 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio's Unique DeltEx D

    2/3/26 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

    Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to only 13.2 months for SOC (+30.3%)Treatment remains well tolerated with no treatment related severe adverse events (SAEs) or dose limiting toxicities (DLTs) observed NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB

    1/12/26 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

    $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio's novel gamma-delta ("γδ") T cell engager through an Investigational New Drug ("IND") application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ("IN8Bio" or the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that it has entered into a definitive securities purchase agreement ("SPA") with certain institu

    12/19/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on IN8bio with a new price target

    Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50

    3/18/24 8:14:30 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on IN8bio with a new price target

    H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00

    8/30/22 7:19:37 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities reiterated coverage on IN8bio with a new price target

    B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously

    1/24/22 9:01:28 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    SEC Filings

    View All

    SEC Form 424B3 filed by IN8bio Inc.

    424B3 - IN8BIO, INC. (0001740279) (Filer)

    1/30/26 4:30:42 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    SCHEDULE 13G - IN8BIO, INC. (0001740279) (Subject)

    1/29/26 3:48:25 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by IN8bio Inc.

    EFFECT - IN8BIO, INC. (0001740279) (Filer)

    1/29/26 12:15:23 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Financials

    Live finance-specific insights

    View All

    IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

    Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos

    6/2/25 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

    100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company devel

    2/11/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

    100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini

    6/13/24 4:01:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IN8bio Inc.

    SC 13D/A - IN8BIO, INC. (0001740279) (Subject)

    10/11/24 6:01:16 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by IN8bio Inc.

    SC 13G - IN8BIO, INC. (0001740279) (Subject)

    10/9/24 5:19:20 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by IN8bio Inc.

    SC 13G/A - IN8BIO, INC. (0001740279) (Subject)

    9/17/24 7:30:50 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Leadership Updates

    Live Leadership Updates

    View All

    IN8bio Appoints Dr. Corinne Epperly to Board of Directors

    Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex

    12/7/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

    Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors

    5/1/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp

    9/8/22 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care